XML 133 R82.htm IDEA: XBRL DOCUMENT
v3.25.4

License Agreements - Narrative (Details) $ in Thousands |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 02, 2025 USD ($) | Nov. 05, 2025 USD ($) | Sep. 26, 2025 USD ($) | Apr. 28, 2025 USD ($) | Mar. 18, 2025 USD ($) | Dec. 31, 2025 USD ($) shares | Oct. 31, 2025 USD ($) | Mar. 31, 2027 USD ($) | Mar. 31, 2026 | Dec. 31, 2024 USD ($) | Dec. 31, 2025 USD ($) employee vote shares | Dec. 31, 2025 USD ($) shares | Mar. 26, 2026 shares
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  |  |  | $ 4,156 |  |  |  | $ 0 | $ 4,156 | $ 4,156 |
Research and development | [1] |  |  |  |  |  |  |  |  |  | 14,034 |  | 138,086 |
Prepaid expenses and other current assets |  |  |  |  |  |  | $ 5,463 |  |  |  | 38 | $ 5,463 | $ 5,463 |
Paragon Option Agreements | Parascent warrant obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercisable (in shares) | shares |  |  |  |  |  |  | 402,731 |  |  |  |  | 402,731 | 402,731 |
Paragon Option Agreements | Forecast | Parascent warrant obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercisable (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 34,566
License Agreement Terms | Paragon Option Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of employees overseeing and coordinating the project | employee |  |  |  |  |  |  |  |  |  |  |  | 2 |  |
Paragon Therapeutics | Paragon Option Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accounts payable and other current liabilities |  |  |  |  |  |  | $ 100 |  |  |  |  | $ 100 | $ 100 |
Paragon Therapeutics | Paragon Option Agreements | Forecast |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of outstanding shares |  |  |  |  |  |  |  |  | 1.00% | 1.00% |  |  |  |
Paragon Therapeutics | License Agreement Terms | Paragon Option Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of employees overseeing and coordinating the project | employee |  |  |  |  |  |  |  |  |  |  |  | 2 |  |
Number of votes | vote |  |  |  |  |  |  |  |  |  |  |  | 1 |  |
Termination period |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |
Research and development |  |  |  |  |  |  |  |  |  |  | $ 13,124 |  | 19,356 |
Paragon Therapeutics | License Agreement Terms | CR-001 | Paragon Option Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  |  |  |  | $ 22,000 |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  | $ 2,500 |  |  |  |  |  |  |  |  |
Restriction period |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |
Percent reduction to royalty payment due to invalid patent |  |  |  |  |  |  |  |  |  |  |  | 30.00% |  |
Termination period due to breach of contract |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |
Sublicense agreement period |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |
Paragon Therapeutics | License Agreement Terms | CR-002 | Paragon Option Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  |  | $ 46,000 |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  | $ 5,000 |  |  |  |  | $ 5,000 |  |  |  |  |  |
Percent reduction to royalty payment due to invalid patent |  |  |  |  |  |  |  |  |  |  |  | 30.00% |  |
Termination period due to breach of contract |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |
Sublicense agreement period |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |
Kelun-Biotech | License Agreement Terms | CR-001 | Collaborative Arrangement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ 20,000 |  |  |  |  | 20,000 |  |  |  |  | $ 20,000 | 20,000 |
Consideration transfer, period |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |
Development milestone payments |  | $ 30,000 |  |  |  |  | 30,000 |  |  |  |  |  |  |
Contract with customer, liability |  |  |  |  |  |  | 15,000 |  |  |  |  | 15,000 | 15,000 |
Contract with customer, refund liability |  |  |  |  |  |  | 5,000 |  |  |  |  | 5,000 | 5,000 |
Deferred revenue, current |  |  |  |  |  |  | 4,200 |  |  |  |  | 4,200 | 4,200 |
Kelun-Biotech | License Agreement Terms | CR-001 | Collaborative Arrangement | License |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract with customer, liability |  |  |  |  |  |  | 10,800 |  |  |  |  | 10,800 | 10,800 |
Kelun-Biotech | License Agreement Terms | CR-001 | Forecast | Collaborative Arrangement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Combination study approval payment |  |  |  |  |  |  |  |  | $ 5,000 |  |  |  |  |
Kelun-Biotech | License Agreement Terms | SKB105 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred |  | 80,000 |  |  |  |  | 80,000 |  |  |  |  |  |  |
Payments to acquire productive assets |  |  |  |  |  |  | 72,000 |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  |  | 8,000 |  |  |  |  |  |  |
Development milestone payment |  | 345,000 |  |  |  |  |  |  |  |  |  |  |  |
Sale based milestone payment |  | $ 902,500 |  |  |  |  |  |  |  |  |  |  |  |
Mid-single digits to low-double digits royalty payment, period |  | 18 months |  |  |  |  |  |  |  |  |  |  |  |
Low-single digits to low-double digits royalty payment, period |  | 24 months |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  | 78,200 |  |  |  |  |  |  |
Prepaid expenses and other current assets |  |  |  |  |  |  | $ 1,800 |  |  |  |  | $ 1,800 | $ 1,800 |
[1] | Includes related party amount of $23,653 for the twelve months ended months ended December 31, 2025 and $13,185 for the period from September 19, 2024 (inception) through December 31, 2024.

X
- Definition Asset Acquisition, Development Milestone Payments, Maximum + References No definition available. + Details
Name: | cbio_AssetAcquisitionDevelopmentMilestonePaymentsMaximum
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, License Agreement, Restriction Period + References No definition available. + Details
Name: | cbio_AssetAcquisitionLicenseAgreementRestrictionPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Maximum Aggregate Milestone Payments + References No definition available. + Details
Name: | cbio_AssetAcquisitionMaximumAggregateMilestonePayments
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Maximum Aggregate, Milestone Payments 1 + References No definition available. + Details
Name: | cbio_AssetAcquisitionMaximumAggregateMilestonePayments1
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Number Of Employees Overseeing And Coordinating Research Project + References No definition available. + Details
Name: | cbio_AssetAcquisitionNumberOfEmployeesOverseeingAndCoordinatingResearchProject
Namespace Prefix: | cbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Number Of Votes, Option Agreement + References No definition available. + Details
Name: | cbio_AssetAcquisitionNumberOfVotesOptionAgreement
Namespace Prefix: | cbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Option Agreement Sublicense Agreement Period + References No definition available. + Details
Name: | cbio_AssetAcquisitionOptionAgreementSublicenseAgreementPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Option Agreement Termination Period + References No definition available. + Details
Name: | cbio_AssetAcquisitionOptionAgreementTerminationPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Option Agreement Termination Period, Breach Of Contract + References No definition available. + Details
Name: | cbio_AssetAcquisitionOptionAgreementTerminationPeriodBreachOfContract
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Royalty Percent Paid, Reduction Due To Invalid Patent + References No definition available. + Details
Name: | cbio_AssetAcquisitionRoyaltyPercentPaidReductionDueToInvalidPatent
Namespace Prefix: | cbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Sale Based Milestone Payment, Low-Single Digits To Low-Double Digits Royalty Payment, Period + References No definition available. + Details
Name: | cbio_AssetAcquisitionSaleBasedMilestonePaymentLowSingleDigitsToLowDoubleDigitsRoyaltyPaymentPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Sale Based Milestone Payment, Mid-Single Digits To Low-Double Digits Royalty Payment, Period + References No definition available. + Details
Name: | cbio_AssetAcquisitionSaleBasedMilestonePaymentMidSingleDigitsToLowDoubleDigitsRoyaltyPaymentPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Sales-Based Milestone Payments, Maximum + References No definition available. + Details
Name: | cbio_AssetAcquisitionSalesBasedMilestonePaymentsMaximum
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Class Of Warrants Or Rights, Percent Of Outstanding Shares + References No definition available. + Details
Name: | cbio_ClassOfWarrantsOrRightsPercentOfOutstandingShares
Namespace Prefix: | cbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract With Customer, Collaborative Arrangement, Combination Study Approval Payment + References No definition available. + Details
Name: | cbio_ContractWithCustomerCollaborativeArrangementCombinationStudyApprovalPayment
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contract With Customer, Collaborative Arrangement, Consideration Transferred, Period + References No definition available. + Details
Name: | cbio_ContractWithCustomerCollaborativeArrangementConsiderationTransferredPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract With Customer, Collaborative Arrangement, Development Milestone Payments, Maximum + References No definition available. + Details
Name: | cbio_ContractWithCustomerCollaborativeArrangementDevelopmentMilestonePaymentsMaximum
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + References No definition available. + Details
Name: | us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contingent consideration recognized as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-27 + Details
Name: | us-gaap_ContractWithCustomerRefundLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | cbio_LicenseAgreementAxis=cbio_ParagonOptionAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=cbio_ParascentWarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_ParagonTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_CR001Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_CR002Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_KelunBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_SKB105Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |